What JRS Pharma does

JRS Pharma, legally JRS PHARMA GmbH + Co. KG, is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, headquartered in Rosenberg and operating as a member of the family-owned JRS Group (founded 1878). The company sells a broad branded portfolio spanning microcrystalline cellulose and powdered cellulose grades (VIVAPUR, EMCOCEL, EMCOMPRESS, EMDEX, ARBOCEL), high-functionality co-processed composites (PROSOLV SMCC, RX, NX, 730, ODT G2), superdisintegrants (VIVASOL, VIVASTAR, EXPLOTAB, VIVAPHARM PVPP, EMCOSOY), binders (VIVAPHARM PVP, PVP/VA), lubricants (PRUV sodium stearyl fumarate, LUBRITAB), carriers (VIVAPUR MCC Spheres), thickeners/stabilizers (VIVAPHARM alginates, VIVAPUR MCG), and the VIVACOAT ready-to-use coating line including the 2026-launched TiO2-free VIVACOAT free. Underlying technology is built on cellulose and alginate chemistries plus co-processing techniques that combine MCC with colloidal silicon dioxide, superdisintegrants and lubricants to deliver differentiated compaction, flow and disintegration performance. Products are cGMP/IPEC GMP and ISO 9001 certified, meeting NF, JP and Ph. Eur. pharmacopoeia monographs.

JRS Pharma monetizes primarily through one-time unit sales of excipients and coatings priced ex-works EUR per kilogram, with publicly visible prices ranging from approximately €19.75/kg for HPMC coating polymer up to €48/kg for enteric VIVACOAT protect E. Distribution runs through direct enterprise sales to pharmaceutical and nutraceutical manufacturers globally, supplemented by an e-commerce platform (coatings-shop.com) for sample and small-volume orders in the coatings segment. Technical services function as a strategic overlay rather than a major revenue stream: Technical Competence Centers in Germany and the U.S. plus application labs in Mexico, Brazil, China and India provide formulation support, customer seminars and on-site troubleshooting, reinforcing product pull-through.

The customer base is split across pharmaceutical (solid and liquid dosage forms), nutraceutical (supplements and chewable tablets), animal health (veterinary suspensions, joint health tablets), and contract biopharma services delivered through wholly-owned subsidiaries Celonic (biotherapeutic CDMO with up to 1,000L GMP manufacturing) and ProJect Pharmaceutics (protein, peptide and ADC formulation). Manufacturing footprint spans three continents with dedicated sites for MCC (Weissenborn), CMS and croscarmellose (Pirna), fiber (Schoolcraft, MI), and alginates (Landerneau, France).

Name

JRS Pharma

Legal name

JRS PHARMA GmbH + Co. KG

Website

https://jrspharma.com

Company type

Private

Founded year

1878

Operating status

Operating

Headcount range

11–50 employees

Short description

JRS Pharma is a privately held German manufacturer of pharmaceutical and nutraceutical excipients and ready-to-use tablet coatings, serving global drug and supplement makers via cellulose- and alginate-based technologies and a three-continent production footprint.

Ownership category

akta.pro rank

Product category

Pharmaceutical Excipients

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Pharmaceutical excipients
• Nutraceutical excipients
• Tablet coating systems
• Direct compression excipients
• Cellulose-based excipients

Headquarters

HQ city

Rosenberg

HQ country

Germany

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Excipients: JRS Pharma generates revenue through the sale of pharmaceutical excipients including microcrystalline cellulose, powdered cellulose, superdisintegrants, binders, lubricants, and alginates for solid and liquid dosage forms.
2. Ready-to-Use Coatings: Sale of VIVACOAT® coating systems for pharmaceutical and nutraceutical tablets, including standard, high-adhesion, enteric, moisture barrier, and specialized coatings.
3. Technical Services: Formulation support, troubleshooting, customer seminars, and technical support through Technical Competence Centers worldwide.
4. Biopharma Services: Through affiliated companies Celonic and ProJect Pharmaceutics - contract development and manufacturing of biotherapeutics, including production cell lines, GMP manufacturing, and formulation services.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

JRS Pharma manufactures and supplies functional excipients and coating systems used by pharmaceutical and nutraceutical companies to formulate solid oral dosage forms such as tablets and capsules. Its portfolio covers binders, fillers, disintegrants, glidants, controlled-release matrix polymers, and ready-to-use film coating systems, complemented by technical services for formulation and coating process support.

Product overview

JRS Pharma offers a comprehensive portfolio of pharmaceutical and nutraceutical excipients and coating solutions, organized into distinct product lines: (1) High Functionality Excipients including PROSOLV® SMCC (silicified MCC), PROSOLV® RX/NX (all-in-one composites), and PROSOLV® 730 (for lipophilic actives); (2) Core Excipients spanning microcrystalline cellulose variants (VIVAPUR®, EMCOCEL®), superdisintegrants (VIVASOL®, VIVASTAR®, EXPLOTAB®, VIVAPHARM® PVPP), binders (VIVAPHARM® PVP, EMDEX®), lubricants (PRUV®, LUBRITAB®), functional fillers (ARBOCEL®, EMCOMPRESS®, COMPACTROL®), thickeners (VIVAPHARM® Alginates, VIVAPUR® MCG), and specialized disintegrants (EMCOSOY®); (3) VIVACOAT® ready-to-use coating systems including TiO2-free formulations, moisture barriers, enteric coatings, and aesthetic coatings; (4) Technical Services with global Technical Competence Centers providing formulation support and troubleshooting. The portfolio serves pharmaceutical, nutraceutical, animal health, and contract manufacturing industries.

Differentiator

Problem solved

Functional benefit

Products and services

• VIVAPUR MCC Spheres

Quantifiable outcome

• 100% satisfactory ratings from top pharmaceutical and nutraceutical companies
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• CeloniccoreStrategic or Co-development PartnerCelonic is a contract manufacturing organization (CMO) offering development and manufacture of biotherapeutics. They provide development of high yield production cell lines, up-stream and down-stream processes, full GMP analytics, and manufacture of active pharmaceutical ingredients (API) in scales up to 1000L cell cultures. Celonic also performs stability studies of drug substances and products. They joined the JRS Pharma Family to meet growing demands for biotech services.
• ProJect PharmaceuticscoreStrategic or Co-development PartnerProJect Pharmaceutics transforms proteins, peptides, and ADCs/Cytotoxics into pioneering drugs. With expertise in design, optimization, and customization of pharmaceutical formulations, they deliver and transfer formulations from pilot lab to large-scale manufacturing under GMP environment. Joined the JRS Pharma Family to expand biopharma services.
• Landerneau Marine Technologies SAScoreTechnology or IntegrationAlginate production facility located on the coast of Brittany, France. Brown algae grow on the continental shelf close to the production site enabling shortest transport routes. Harvesting is regulated by local authorities for optimal sustainability. By-products are re-used or recycled as fertilizer for local agricultural production.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• BASF: Global chemical giant with a broad pharmaceutical excipients and active ingredient portfolio. Directly comparable to JRS Pharma in binders, disintegrants, and coatings, though BASF spans a far wider industrial chemicals footprint.
• IFF (DuPont Nutrition & Biosciences): Acquired DuPont's N&B division and offers a large portfolio of pharmaceutical excipients and coatings under the Health & Biosciences segment. Comparable in cellulose-based excipients and broader specialty ingredients.
• Evonik: German specialty chemicals company with a healthcare-focused excipients portfolio including silica, polyesters, and amino acid derivatives. Comparable in serving global pharma manufacturers with high-purity functional excipients.
• Shin-Etsu Chemical: Major Japanese specialty chemicals producer offering HPMC, PVP, and other pharmaceutical-grade excipients. Directly competitive with JRS Pharma's VIVAPHARM® HPMC and PVP product lines.

Direct peers

• Roquette: French-headquartered global leader in pharmaceutical excipients including microcrystalline cellulose, starches, and cyclodextrins. Closest direct competitor to JRS Pharma across both pharma and nutraceutical excipients.
• DFE Pharma: Netherlands-based dedicated pharmaceutical excipients supplier offering lactose, MCC, superdisintegrants, and inhalation-grade materials. Highly comparable in scale and focus to JRS Pharma's excipient core business.
• Colorcon: Specialist in film coatings, modified release technologies, and excipients for the pharmaceutical and nutraceutical industries. Direct competitor to JRS Pharma's VIVACOAT® coating line and ready-to-use formulations.
• Ashland: US-based specialty chemicals company with a pharmaceutical division offering tablet coatings, disintegrants, and binders. Directly comparable in serving pharma and nutraceutical excipient needs.

Emerging players

• Seppic (Air Liquide Healthcare): Specialty ingredient supplier within Air Liquide offering pharmaceutical and nutraceutical excipients including polymers and coating systems. Comparable in functional coatings and excipient innovation.
• Kerry Group: Irish taste and nutrition company with a pharmaceutical excipients offering including binders, coatings, and taste-masking technologies. Increasingly comparable to JRS Pharma's nutraceutical-focused portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/about/privacy
• LinkedInlinkedin.com/company/jrs-pharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JRS Pharma